Literature DB >> 14680717

Differential diagnosis using the MMPI-2: Goldberg's index revisited.

Jos I M Egger1, Peter A M Delsing, Hubert R A De Mey.   

Abstract

BACKGROUND: The Minnesota Multiphasic Personality Inventory (MMPI-2) often supports clinical decision-making in complex diagnostic problems like differentiating neurosis from psychosis and psychosis from bipolar disorder. The MMPI Goldberg index, an arithmetical combination of five clinical scales, has been considered to provide a good estimate for discriminating between neurotic and psychotic profiles. Similarly, the MMPI-2 Personality Psychopathology Five (PSY-5) scales have been found to be useful in differentiating diagnostic categories.
METHOD: This study evaluates these findings in a sample of psychiatric patients diagnosed with depressive, psychotic, or bipolar disorder using ANOVA and discriminant analysis.
RESULTS: Results corroborate the validity of Goldberg's index and find MMPI-2 PSY-5 scale Disconstraint to significantly differentiate between psychotic and bipolar-I disorder.
CONCLUSION: The MMPI-2 Goldberg index and PSY-5 scales can offer a useful contribution to the differential diagnosis of depressive, psychotic and bipolar disorder.

Entities:  

Mesh:

Year:  2003        PMID: 14680717     DOI: 10.1016/j.eurpsy.2003.06.008

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  2 in total

1.  Identifying family members who are likely to perceive benefits from providing care to a person with a primary malignant brain tumor.

Authors:  Alyssa Newberry; Jean Kuo; Heidi Donovan; Barbara Given; Charles W Given; Richard Schulz; Paula Sherwood
Journal:  Oncol Nurs Forum       Date:  2012-05-01       Impact factor: 2.172

2.  Exploring spirituality in family caregivers of patients with primary malignant brain tumors across the disease trajectory.

Authors:  Alyssa G Newberry; Chien-Wen Jean Choi; Heidi S Donovan; Richard Schulz; Catherine Bender; Barbara Given; Paula Sherwood
Journal:  Oncol Nurs Forum       Date:  2013-05-01       Impact factor: 2.172

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.